Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|July 9, 2013
Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric surveyGiovanni D'Arena, Luca Laurenti, Marta Coscia, et al.
International Journal of Cancer|October 17, 2024
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 studyEliana Bignotti, Vittorio Simeon, Laura Ardighieri, et al.
The International Journal of Biological Markers|November 8, 2024
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trialStefano Indraccolo, Simona Signoriello, Ilaria Piga, et al.
Epidemiologia E Prevenzione|January 8, 2021
[Covid-19 and clinical-epidemiological research in Italy: proposal of a research agenda on priority topics by the Italian association of epidemiology]Giovannino Ciccone, Silvia Deandrea, Antonio Clavenna, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 11, 2023
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialLuca Forlani, Loris De Cecco, Vittorio Simeon, et al.
British Journal of Haematology|April 19, 2017
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre studyPellegrino Musto, Luca Maurillo, Vittorio Simeon, et al.
Cancers|April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer PatientsCrescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Annals of Hematology|October 25, 2018
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 27, 2023
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resectionFilippo Pelizzaro, Franco Trevisani, Vittorio Simeon, et al.
International Journal of Cancer|May 14, 2026
Cardiovascular disease incidence and cancer risk in two large European prospective cohortsEmma Fontvieille, Vivian Viallon, Laia Peruchet-Noray, et al.
Pageof 15